MedTrace Logo

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2020-12-22

Study results available
· View outcomes & findings →

Summary

To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.

Conditions

Interventions

DRUG

Sildenafil citrate

oral, 20 mg, tid

DRUG

Sildenafil citrate

oral 1 mg, tid

DRUG

Sildenafil citrate

oral 5 mg, tid

DRUG

Sildenafil citrate

oral 20 mg, tid

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-08
Primary Completion
2010-05-25
Completion
2010-05-25

Countries

  • United States
  • Belgium
  • Brazil
  • Bulgaria
  • China
  • Greece
  • India
  • Italy
  • Latvia
  • Malaysia
  • Netherlands
  • Philippines
  • Poland
  • Romania
  • Russia
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430716 on ClinicalTrials.gov